Growth & Hormones

Growth-hormone secretagogues and GHRH analogues used in endocrinology research. This category covers CJC-1295 no DAC, a GHRH analogue studied for pulsatile secretion and GHRH receptor pharmacology; Ipamorelin, a selective ghrelin-receptor agonist examined for GH release with minimal effect on other hormone axes; and Tesamorelin, a stabilised GHRH analogue studied in lipid-metabolism models.
This category contains two distinct receptor classes that are constantly confused. Tesamorelin and CJC-1295 are GHRH analogues acting at the GHRH receptor; Ipamorelin is a ghrelin mimetic acting at GHS-R1a, a different receptor entirely. The WHO stem -relin marks a releasing-hormone agonist and appears in both, which is part of why they are mixed up — the stem describes function, not target. Because the two classes act through separate pathways converging on the same output, study designs frequently examine them in combination.
The length difference between the classes drives everything practical. GHRH analogues run 29 to 44 residues because their receptor requires most of that sequence; ghrelin mimetics work at five or six because the pharmacophore their receptor recognises is small. A 44-residue chain costs far more per milligram — more coupling steps, lower yield, harder purification — and deletion sequences become the dominant impurity, close enough to the product that HPLC may not resolve them. For the long analogues, mass-spectrometric identity confirmation carries more weight than the purity percentage. Our CJC-1295 versus Ipamorelin comparison works through the contrast.
Each compound is independently analysed for purity by HPLC and for identity by mass spectrometry before listing. Batch-matched Certificates of Analysis are available on request. Lyophilised powder, for in-vitro research and laboratory use only.